EGFR and non-small cell lung carcinoma: Therefore, we need effective strategies for the treatment of patients with MET-amplified NSCLC that has relapsed from first- or second-generation EGFR-TKI treatment or patients who develop acquired resistance to osimertinib due to MET amplification and protein hyperactivation.